3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

SCREENING AND ENROLLMENT IN TWO COHORT STUDIES WITH DIFFERENT PROCEDURES AND BENEFITS IN LUSAKA, ZAMBIA

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. WePp0205

Ntamwemezi J.-B.
Rwanda-Zambia HIV Research Group., Lusaka, Zambia

INTRODUCTION: The HIV heterosexual transmission (HT) study provides counseling and condom skills to prevent HIV transmission, whereas the family planning (FP) study provides family planning counseling and contraceptive methods. Both studies recruit from Voluntary Counseling and Testing (CVCT) centers and participants are followed at the same research site.

METHODS: HT study participants receive outpatient health care at the project clinic and participants come at 3-month intervals. Per visit reimbursement is $5. FP study participants receive reproductive health care at the research clinic. Women in the FP study return quarterly while their male partners return annually. Per visit reimbursement is $7. Identical medical and laboratory data collection procedures are used in the two studies. FP participants complete one additional behavioral assessment tool.

RESULTS: Between June 2002 and January 2005, a total of 7679 couples were tested in Lusaka. 1098 discordant couples were eligible for the HT study of whom 731 (67%) were enrolled a mean of 16.3 days after screening. 762 couples were eligible for the FP study of whom 518 (68%) were enrolled a mean of 15.5 days after screening. The median (12 days for HT and 11 for FP) and ranges (1 – 93 for HT and 1 – 88 for FP) were similar and the mode (4 days) was the same for both studies.

CONCLUSIONS: The enrollment rate for the two studies was similar, indicating that the different benefits and procedures associated with each study did not significantly affect couples’ decisions to participate. While a broad range of outpatient services is appreciated as a benefit for HT participants, it is costly in personnel time and medication. A higher per visit reimbursement with health care limited to reproductive health resulted in similar enrollment rates.

Download PDF of this abstract.

050724
Prevention | WePp0205 | Ntamwemezi J.-B.
Planning For Vaccine Efficacy Trials

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.